The generic version of Symproic is potentially releasable after 13th May 2033. This date coincides with the expiration of the last patent (US10952968) that Bdsi holds on Symproic. Furthermore, drug patent challenges against Symproic can be filed as of 23rd March 2021.
Symproic, containing the active ingredient naldemedine tosylate, is primarily used for the treatment of opioid-induced constipation.
Symproic, an opioid-induced constipation treatment drug, holds a total of 4 patents, none of which have expired. The patent with the latest expiration date (US10952968) expires on 13th May 2033. See Symproic generic and patent details below: